Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
about
Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumorsSurgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from AsiaBevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.An analysis of trends and growth factor receptor expression of GI carcinoid tumorsPancreastatin predicts survival in neuroendocrine tumors.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Blood transcript analysis and metastatic recurrent small bowel carcinoid management.Microencapsulation of small intestinal neuroendocrine neoplasm cells for tumor model studiesGastric neuroendocrine tumours.Multidisciplinary reference centers: the care of neuroendocrine tumors.Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China.Multimodal management of neuroendocrine liver metastases.Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.Identification of candidate serum proteins for classifying well-differentiated small intestinal neuroendocrine tumorsInfluence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinicaSerum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution.Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumorsClinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedImplications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Gastric carcinoids: between underestimation and overtreatment.Consensus on biomarkers for neuroendocrine tumour diseaseAccomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.Disadvantage of survival outcomes in widowed patients with colorectal neuroendocrine neoplasm: an analysis of surveillance, epidemiology and end results databaseThe pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.Atypical metastatic carcinoid of the uterine cervix and review of the literature.The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.Neuroendocrine neoplasms of the gut and pancreas: new insights.
P2860
Q21089988-47A1C051-1CE3-424F-9AD4-D0C8103775F3Q30884528-15389AC3-4242-44BC-B1EE-79C5AB010615Q31170918-B1EA63AE-1C91-4185-9C15-CB826A162FFFQ33601383-FA906829-2204-466D-AD72-73D266F4DAC3Q33737587-E8973579-A931-44C8-BCB7-43AE43DA0736Q33985773-B7E9B461-C74C-4434-AAF3-5C00D4DD2171Q34016884-03AEE48B-ED88-415F-8C09-B8B4B7F7B811Q34031906-1E159FF5-0A87-4C17-82DE-F5135DA60068Q34107681-09E2C34A-6B2B-449C-8E01-28CB754E8327Q34204609-A1952B5F-1751-442C-A473-8C93C09B136EQ34306680-7D3AE9A7-911D-47B2-9ADB-DA1DD002E21EQ34335130-0C953CC6-A8D0-4439-AE38-5EB5ADC6750DQ34495609-3150F31D-0A6C-4FC5-AE2B-748FD67A1A13Q34528199-BCC4BB24-D4B8-4429-B9E2-1DC36A3D8163Q34610406-CA13D6D9-2B48-43AC-B75B-4F3A26B4CBF9Q35055381-51941794-3E91-4404-9518-04583B153F70Q35545959-26109D03-EBAA-4C33-8CAD-DE908C9CDA2CQ35550241-8AB777EA-D1AC-41F7-B1D4-F07177531DB2Q35640506-40B0A804-7920-44F0-A8DB-2595DC5769EEQ35909807-50D426D7-ACCC-4438-8039-0BFAC8E7854EQ36009085-6C7E3612-4844-4E9E-8C2C-C0F5722B4C47Q36359089-5D2464B9-D11E-4020-8E7C-83FCFCF03874Q36790050-D3E85B8B-D8CD-4AF5-A4A4-E26E1AE99CADQ36831573-99DF463A-8824-412D-8374-D231E47A1215Q36871673-DA8DF4AF-BAE1-4256-ADE4-AA088D1FB60CQ36943954-E9281B1D-5748-4F23-80BA-13FF3D3A893BQ37085554-DF1358B5-0D64-46E1-A9BD-4939B833AB20Q37116888-8527FB33-2644-4E99-853A-E8C565D269F4Q37117596-2115CA6A-1255-4AED-9AD5-3947FB623423Q37192619-FCF4B5F9-53A4-474A-9C60-0428342E6AC3Q37255681-B71E6195-BD00-42D8-9936-46D81486A1BFQ37468838-AF55D4A2-3482-4116-BAAA-4FBD863E9229Q37624511-B003B549-9617-4A0E-A4ED-B65B05A1A4E7Q37634917-DAC678BD-8EC4-438A-8FE2-23C4F3AEED8CQ37696289-E4C5BCEE-5D9F-419D-A625-61C9B1890399Q37846130-296C5E26-DAEE-4AB4-BDD0-7026FC562220Q37849836-56A3BD1F-8212-4269-ABED-D4ACE180F76FQ37869391-E0A0D5D7-6FBD-4340-992B-C16DC6E8673EQ37875054-58F78AC4-6878-4AB7-9017-1A984EE83C42Q37909911-81DD10A2-DE17-4905-8735-4A3E53B3C5F6
P2860
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
@en
type
label
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
@en
prefLabel
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
@en
P2093
P2860
P356
P1476
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
@en
P2093
Daniel C Chung
Elizabeth Snyderwine
Irvin M Modlin
Robert T Jensen
Steven F Moss
P2860
P304
P356
10.1093/JNCI/DJN275
P407
P577
2008-09-09T00:00:00Z